Yong-Jian Liu

Comparative pharmacovigilance of glycaemic adverse-event reporting for alpelisib and capivasertib: A disproportionality analysis of the FDA adverse event monitoring system

Alpelisib and capivasertib inhibit adjacent nodes of the phosphatidylinositol 3-kinase/protein kinase B pathway and disrupt glucose homeostasis. Their overlapping fulvestrant-based treatment contexts support comparison despite different biomarker eligibility. To compare the post-marketing adverse-event repor...